Dose selection in seamless phase II/III clinical trials based on efficacy and safety. - Wikidata - wikimedia - TriplyDB

Dose selection in seamless phase II/III clinical trials based on efficacy and safety.

Dose selection in seamless phase II/III clinical trials based on efficacy and safety.

http://www.wikidata.org/entity/Q46029341

about

Optimizing the data combination rule for seamless phase II/III clinical trials.Adaptive clinical trial designs in oncology.Controlled multi-arm platform design using predictive probability.A modified varying-stage adaptive phase II/III clinical trial design.Estimation after subpopulation selection in adaptive seamless trials.A comparison of methods for treatment selection in seamless phase II/III clinical trials incorporating information on short-term endpoints.Confidence intervals for confirmatory adaptive two-stage designs with treatment selection.Adaptive Multivariate Global Testing.Conditionally unbiased estimation in phase II/III clinical trials with early stopping for futility.An Adaptive Staggered Dose Design for a Normal Endpoint.A conditional error function approach for subgroup selection in adaptive clinical trials.A hybrid procedure for detecting global treatment effects in multivariate clinical trials: theory and applications to fMRI studies.Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods.

P2860

Q30860286-0E1FE23E-9358-427A-8B30-E1766521125E Q35206844-EAC0943D-40A4-4479-9AB5-5A6B732ECDE7 Q37289826-CAA5CC04-4D47-4BBD-AF5A-B029134691BB Q39708750-470E7D6F-3A81-491C-95D0-912FD1FCB899 Q41027668-6CEC2E07-59B7-499E-9EF3-E0E8FADF7232 Q42130183-A04EA576-ED37-4554-8026-31D54D2ECE4B Q42268244-18F2374F-0547-4056-B68C-093FEBAC34F5 Q42753983-08E67FB1-3CBB-4144-AB99-03C6BF6AD779 Q42926272-CFD0C7AE-7BF1-4996-A076-193F77BFA55D Q44582568-4E996971-4A58-479A-9C7B-1C9E53410CB2 Q46406244-43FC3271-F916-4E56-8E7A-2FA3A2AE1E09 Q48778239-981F451A-701E-4148-A9BB-9925E5A5F1B0 Q51397243-C3D08DD4-654D-4D17-9874-3595E3B8C229

P2860

Dose selection in seamless phase II/III clinical trials based on efficacy and safety.

http://www.wikidata.org/entity/Q46029341

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Dose selection in seamless phase II/III clinical trials based on efficacy and safety.

@en

Dose selection in seamless phase II/III clinical trials based on efficacy and safety.

@nl

type

label

Dose selection in seamless phase II/III clinical trials based on efficacy and safety.

@en

Dose selection in seamless phase II/III clinical trials based on efficacy and safety.

@nl

prefLabel

Dose selection in seamless phase II/III clinical trials based on efficacy and safety.

@en

Dose selection in seamless phase II/III clinical trials based on efficacy and safety.

@nl

P1433

Q46029341-2EDFFD2A-1799-4341-A59C-D4B0DF8F28F9

P1476

Q46029341-71BD138E-963B-42AC-B1B5-8965C762FAA8

P2093

Q46029341-E635EA86-B68B-4761-8E96-ADE5C42C0BA2

P2860

Q46029341-25D5055F-CE52-4B1F-AEAA-AA77C9CE297C

Q46029341-48DECB1A-DC0A-4636-8AD2-E816581F2FFE

Q46029341-6A18AE48-3541-4042-87AA-1EFF2D38A295

Q46029341-7237C87D-61BB-4D61-B880-7921A778A3F0

Q46029341-910B0978-46D1-4C70-BB23-EF75B0C121EB

Q46029341-9F48665C-0AFF-4F76-A7BA-C8B2F899540B

Q46029341-A6EF390D-A813-4440-AE6A-6D02DFA2AB0C

Q46029341-B6AFF1F2-4DD7-4994-A9A0-AB835C26E369

Q46029341-BA78480F-4036-4EA9-A752-0A34B4E4D484

Q46029341-E48DBF5D-F341-49F4-B049-984A1C91F2E6

P304

Q46029341-BC1B379E-9550-4EDD-9C3C-A68FB733C643

P31

Q46029341-BC7C761D-C780-4363-A3F7-72AB10E36C61

P356

Q46029341-3DEA67EC-D9D2-4FBA-9152-995964EB5198

P407

Q46029341-E38B4DE8-5258-41D8-A72D-12D0FAB61927

P433

Q46029341-2F0BED49-E30C-4F2C-8DCB-3B354F97B224

P478

Q46029341-A82C1F60-A19B-419A-8BB6-10FAD1DDAC75

P50

Q46029341-D623C7A3-CD20-452D-95DC-FBF8536D1D8A

Q46029341-E89AA852-A0CC-4167-A026-92E34EE0BE2C

P577

Q46029341-D8C1D282-DB3A-4052-856F-669B7F42D621

P5875

Q46029341-A0770875-043F-4DFB-83B0-6264947D4649

P698

Q46029341-080DAE88-4D0A-4D52-9ED0-94F9E04FBCA2

P921

Q46029341-5E808E04-CF72-46FE-AB9A-A32D501DC79D

Q46029341-B1D246C5-F8A6-43E6-A92E-2E396BAEE18A

P356

P1433

Statistics in Medicine

P1476

Dose selection in seamless phase II/III clinical trials based on efficacy and safety.

@en

P2093

Jane L Hutton

http://www.w3.org/2001/XMLSchema#string

P2860

On closed testing procedures with special reference to ordered analysis of variance

Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts.

Sequential designs for phase III clinical trials incorporating treatment selection.

Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.

Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios.

Bayesian decision procedures for dose-escalation based on evidence of undesirable events and therapeutic benefit.

Seamlessly expanding a randomized phase II trial to phase III.

Truncated product method for combining P-values.

Discrete sequential boundaries for clinical trials

Recursive Combination Tests

P304

917-936

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/SIM.3522

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Peter K. Kimani

P577

2009-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23799327

http://www.w3.org/2001/XMLSchema#string

P698

19152231

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

phase III clinical trial